Relationship between the serum alanine aminotransferase level at the end of interferon treatment and histologic changes in wild-type and precore mutant Hepatitis B Virus infections

Journal of Viral Hepatitis

Volumn 3, Issue 3, 1996, Pages 137-142

  Bayraktar, Y ^a,b   Koseoglu, T ^a   Temizer, A ^a   Kayhan, B ^a   Van Thiel, D H ^b   Uzunalimoglu, B ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Chronic hepatitis B; Ferritin; Interferon; Iron; Mutant virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; FERRITIN; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENETIC VARIABILITY; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, MICROBIAL; FEMALE; FERRITINS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; VARIATION (GENETICS);

EID: 0030133797     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1996.tb00004.x     Document Type: Article

References (22)

1. Coursaget P, Yvonnet B, Chotard J et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986; 2: 1143.
2. Wu J-S, Ko Y-C, Lio W-T. Hepatitis B virus type 2. Lancet 1988; 1: 990.
3. Echevarria JM, Leon P, Domingo CJ et al. Atypical hepatitis B virus in Spain. Lancet 1988; 2: 1315.
4. Akahane Y, Yamanaka T, Suzuki H et al. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99: 1113.
5. Brunetto MR, Stemler M, Schodel F et al. Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 1989; 21: 151.
6. Carman WF, Hadziyannis S, McGarvey MJ et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588.
7. Naoumov NV, Schneider R, Grotzinger T et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 538.
8. Bonino F, Rizzetto M, Will H. Hepatitis B virus unable to secrete e antigen. Gastroenterology 1991; 100-1138.
9. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-374.
10. Perrillo MP. Interferon in the management of chronic hepatitis B. 1993. Dig Dis Sci 1993; 38: 577-593.
11. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763.
12. Trepo C, Rougier P, Bizollan T et al. Combination therapy with ARA-AMP and interferon of chronic active hepatitis. Br J Hepatol 1991; 13: 3.
13. Sutnic AL, Blumberg BS, Lutsbader ED. Alleviated serum iron levels and persistent Australia antigen (HBsAg). Ann Int Med 1974; 81: 855-856.
14. Lutsbader ED, Hann H-WL, Blumberg BS. Serum ferritin as a predictor of host response to HBV infection. Science 1983; 220: 423-425.
15. Deugnier Y, Battistelli Y, Joufonelle H et al. Hepatitis B virus infection markers in genetic hemochromatosis. J Hepatol 1991; 13: 286-290.
16. Lustbader ED, Hann HL, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220: 423-425.
17. Senba M, Nakamura T, Itakura H. Statistical analysis of relationship between iron accumulation and hepatitis B surface antigen. Am J Clin Pathol 1985; 84: 340-342.
18. Felton C, Lustbader ED, Merten C et al. Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci USA 1979; 76: 2438-2421.
19. Perez R, Pravia R, Linares A et al. Response related factors in recombinant interferon alpha 2b treatment of chronic hepatitis C. Viral hepatitis management standards for the future. Abst Post 1992: 105.
20. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442-3449.
21. Van Thiel DH, Friedlander L, Fagiuoli S et al. Response to interferon-alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-415.
22. Olynyk JK, Reddy KR, Di Bisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-1109.